Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-245-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- with 10-week premating period
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Reaction mass of (E)-3,4,5,6,6-pentamethylhept-3-en-2-one and 3,5,6,6-tetramethyl-4-methyleneheptan-2-one
- EC Number:
- 946-245-5
- Molecular formula:
- C12H22O
- IUPAC Name:
- Reaction mass of (E)-3,4,5,6,6-pentamethylhept-3-en-2-one and 3,5,6,6-tetramethyl-4-methyleneheptan-2-one
- Test material form:
- liquid
- Details on test material:
- According to ECHA communication with reference to Annotation number: SUB-C-2114629169-42-01/F, the substance ID for Koavone has been changed with EC# from 939-627-8 to 946-245-5, and the IUPAC name from Reaction mass of (3R,5R)-3,5,6,6-tetramethyl-4-methylideneheptan-2-one and (3R,5S)-3,5,6,6-tetramethyl-4-methylideneheptan-2-one and (E)-3,4,5,6,6-pentamethylhept-3-en-2-one to Reaction mass of (E)-3,4,5,6,6-pentamethylhept-3-en-2-one and 3,5,6,6-tetramethyl-4-methyleneheptan-2-one.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Wistar strain: Crl:WI(Han)
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at initiation of treatment: 5 (males) - 6 (females) weeks
- Weight at initiation of treatment: about 100 g (males) - 130 g (females)
- Housing: in macrolon cages with wood shavings (Lignocel, type 3/4) as bedding and shreds of paper (Enviro-dri) as environmental enrichment. Premating period: 4 rats of the same sex/cage; mating period: one male and one female per cage; after mating, males were returned to their group cage and females were housed individually during gestation and with their litter during lactation.
- Diet: powdered Rat and Mouse no. 3 breeding diet, RM3 (SDS Special Diets Services, Witham, England), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
- Allocation: by computer randomization proportionately to body weight
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2
- Humidity (%):45-65
- Air changes (per hr): about 10
- Photoperiod (hrs dark / hrs light): 12 hours dark, 12 hours light
IN-LIFE DATES:
From 11 May 2011 to 1-2 August (males) / 15-22 August (females) 2011 (from start treatment to end in-life period)
Administration / exposure
- Route of administration:
- oral: feed
- Details on exposure:
- The test material was mixed into the diet using a mechanical blender. Fresh batches of the experimental diets were prepared about once every 4-5 weeks, divided into daily amounts, packed in plastic bags, and stored in a freezer (<-18°C). Once daily in the afternoon (generally between 3-4 PM on working days), a fresh portion from the freezer was given to the animals. This frequency and timing of feed refreshing was applied because stability analyses showed that the concentration of the test substance in the feed decreased during storage at room temperature (by 18-27% after one day).
- Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: maximally 7 days.
- Proof of pregnancy: sperm in vaginal smear (made in the morning), referred to as day 0 of pregnancy.
- After successful mating, each pregnant female was caged individually for the birth and rearing of the pups.
- Sperm positive females that appeared non-pregnant (one control and one high-dose female) were sacrificed 27-28 days after copulation.
- One high-dose female that did not show evidence of copulation was housed individually after the last day of the mating period and sacrificed 29 days after the start of the mating period. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose confirmation analyses were conducted using a HPLC method with UV detection (at 247 nm) after extracton with acetonitrile.
Stability under simulated experimental conditions was checked by analysis of samples immediately after diet preparation and after storage in the animal room (open container) for one day or in a freezer (<-18°C) for at least 5 weeks. The test substance was stable in the diet when stored in a freezer. The concentrations measured after one day storage in the animal room were 18% (low dose), 27% (mid dose) and 22% (high dose) lower than those measured at the start of the storage period.
Homogeneity and achieved concentration were confirmed by analysis of samples from diets prepared shortly before initiation of treatment. For homogeneity, 5 samples per concentration (low, mid, high dose) were analysed. The measured concentrations were generally within 90-110% of the nominal concentrations. - Duration of treatment / exposure:
- Males: up to 83 days (70 days premating, 7 days mating, 5-6 days until sacrifice)
Females: up to 103 days (70 days premating, 1-4 days mating, 21/22 days gestation, 4-6 days lactation) - Frequency of treatment:
- Continuous administration via the diet (fixed dietary concentrations)
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 200, 750 and 2500 mg/kg diet
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
Premating males: 16 (low), 58 (mid), 202 (high) mg/kg body weight/day
Basis:
other: calculated from nominal dietary concentrations; due to instability actual concentrations were lower (loss is maximally 30%)
- Remarks:
- Doses / Concentrations:
Premating females: 15 (low), 56 (mid), 171 (high) mg/kg body weight/day
Basis:
other: calculated from nominal dietary concentrations; due to instability actual concentrations were lower (loss is maximally 30%)
- Remarks:
- Doses / Concentrations:
Gestation females: 14 (low), 51 (mid), 165 (high) mg/kg body weight/day
Basis:
other: calculated from nominal dietary concentrations; due to instability actual concentrations were lower (loss is maximally 30%)
- Remarks:
- Doses / Concentrations:
Lactation females: 14 (low), 45 (mid), 195 (high) mg/kg body weight/day
Basis:
other: calculated from nominal dietary concentrations; due to instability actual concentrations were lower (loss is maximally 30%)
- No. of animals per sex per dose:
- 12 rats/sex/dose
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: selection based on 2-week range-finding study.
- Rationale for animal assignment (if not random): computerised randomisation proportionately to body weight. Animals were allocated one day before initiation of treatment.
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS:
- Time schedule: at least once daily.
- Additional checks: daily afternoon check for dead or moribund animals.
DETAILED CLINICAL OBSERVATIONS (in standard arena): Not conducted.
BODY WEIGHT:
Males: on day of allocation, at initiation of treatment, weekly thereafter, and on the day of scheduled sacrifice.
Females: on day of allocation, at initiation of treatment, weekly during the premating and mating period, on days 0, 7, 14 and 21 during presumed gestation (mated females), and on days 1 and 4 of lactation. Non-mated females were weighed one per week after the mating period.
FOOD CONSUMPTION:
- Except during the mating period, food consumption was measured from day 0 onwards on the same days as body weight was meausred. Results were expressed as g feed/animal/day and g feed/kg body weight/day.
WATER CONSUMPTION: Not measured.
OPHTHALMOSCOPIC EXAMINATION: Not conducted.
HAEMATOLOGY:
- Time schedule for collection of blood: at end of premating period (week 10)
- Anaesthetic used for blood collection: Yes (carbon dioxide/oxygen)
- Animals fasted: yes (overnight)
- How many animals: 5/sex/group (from different cages)
- Parameters examined:
. Red blood: haemoglobin, red blood cells, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, reticulocytes
. White blood: total white blood cells, differential white blood cells (absolute and relative)
. Coagulation: thrombocytes, prothrombin time
CLINICAL CHEMISTRY:
- Time schedule for collection of blood: at end of premating period (week 10)
- Anaesthetic used for blood collection: Yes (carbon dioxide/oxygen)
- Animals fasted: Yes (overnight)
- How many animals: 5/sex/group (from different cages)
- Parameters examined: alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamuyl transferase, total bilirubin, total protein, albumin, albumin/globulin ratio, glucose, total cholesterol, triglycerides, creatinine, urea, electrolytes (calcium, chloride, potassium, sodium, inorganic phosphate).
URINALYSIS: Not conducted.
NEUROBEHAVIOURAL EXAMINATION:
Time schedule for examinations: towards the end of the premating period (in week 9)
Battery of functions tested:
- Grip strength (forelimb and hindlimb)
- Motor activity
- Observational screen including sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive). Screen components:
Autonomic: lacrimation (R), salivation(R), pupil response to light(Q), palpebral closure(R), piloerection(Q), defaecation(C), urination(C);
Neuromuscular: gait(D,R), mobility(R), forelimb and hindlimb gripstrength(I), landing foot splay(I), righting reflex(R);
Sensorimotor: response(R) to tail pinch, click, touch and approach of a visual object;
Convulsive: clonic and tonic movements(D);
Excitability: ease of removal(R), handling reactivity(R), arousal(R), vocalizations(Q);
Activity: rearing(C), posture(D);
Physiological: body temperature(I)
(C=count data; D=descriptive rank data; I=interval or continuous data; Q=quantal data; R=rank order data). - Oestrous cyclicity (parental animals):
- Not conducted.
- Sperm parameters (parental animals):
- The left cauda epididymis and the left testis of 5 males/group were used for sperm examinations.
Sperm parameters examined in all groups (by Hamilton Thorne Integrated Visual Optical System, IVOS):
- sperm motility
- sperm count (cauda epididymal sperm reserve)
Sperm parameters examined in the control and high-dose group:
- sperm morphology (epididymal sperm smears were prepared and stained for all groups; 200 spermatozoa/smear of the control and high-dose animals were examined).
- number of homogenization-resistant spermatids (enumeration by the IVOS)
- daily sperm production (calculated from testicular sperm count) - Litter observations:
- PARTURITION AND LITTER EVALUATION:
At the end of the gestation period (gestation day 21), females were examined twice daily for signs of parturition. Any difficulties occurring during parturition were recorded. To keep nest disturbance to a minimum the litters were examined only once daily for dead pups.
PARAMETERS EXAMINED:
The following parameters were examined in F1 offspring on days 1 and 4 of lactation:
- total litter size
- numbers of each sex
- numbers of stillbirths, live and dead pups
- grossly malformed pups/clinical observations
- pup weight (pups were weighed individually; mean pup weight was calculated per sex and for both sexes combined) - Postmortem examinations (parental animals):
- GROSS PATHOLOGY: Yes (all male and female parent animals)
Animals were sacrificed by exsanguination from the abdominal aorta under carbondioxide/oxygen anaesthesia.
Males were sacrificed about one week after the mating period. Females were sacrificed at or shortly after day 4 of lactation.
ORGAN WEIGHTS:
All male animals: testes, epididymides
5 Animals/sex/group: adrenals, brain, heart, kidneys, liver, spleen, thymus
Paired organs were weighed together.
Organ weights relative to terminal body weight were calculated.
TISSUES PRESERVED:
In neutral aqueous phosphate-buffered 4% formaldehyde solution or Bouin's fixative (testes)
All parental animals:
Ovaries (after counting of the corpora lutea)
Uterus (after counting of the implantation sites)
testes
epididymides
seminal vesicles
prostate
all gross lesions
5 Parental animals/sex/group:
adrenals
bone marrow (femur)
brain (3 levels: cerebrum, cerebellum, medulla/pons)
heart
small and large intestine (including Peyer's patches)
kidneys
liver
lung
lymph nodes (mesenterial and axilary)
peripheral nerve (tibial)
spinal cord (3 levels: cervical, mid-thoracic, lumbar)
spleen
stomach
thymus
thyroid
trachea
urinary bladder
HISTOPATHOLOGY:
Control and high-dose: all preserved organs and tissues.
Low- and mid-dose: kidneys (males only) and gross lesions.
Paraffin sections were stained with haematoxylin-eosin or PAS haematoxylin (testes).
Additional kidney sections of the male control and high-dose animals were processed for immunocytochemical staining of alpha 2-microglobuline using a mouse-anti-rat alpha 2-microglobuline antibody (SSI, Copenhagen, Denmark). - Postmortem examinations (offspring):
- GROSS NECROPSY
Stillborn pups and pups that died during the study were examined for gross abnormalities (external and internal examination). - Statistics:
- - Body weight (gain), food consumption, haematology, clinical chemistry, organ weights, continuous behavioural data, total distance moved in motor activity test: one-way analysis of variance followed by Dunnett's multiple comparison test.
- Habituation of motor activity: repeated measures analysis of variance on time blocks.
- Behaviour - rank data: Kruskal-Wallis non-parametric one-way analysis of variance followed by Dunnett's multiple comparison test.
- Behaviour - categorical data: Pearson's chi-square analysis.
- General clinical signs and histopathology: Fisher's exact probability test.
Reproduction toxicity parameters:
- Fisher's exact probability test was used to evaluate the number of mated and pregnant females, the number of pregnant females with implants but no pups, females with live pups, females with stillborn pups, live and dead fetuses or pups and the numbers of litters lost entirely.
- Kruskal-Wallis nonparametric analysis of variance followed by the Mann-Whitney U test was used to evaluate pre-coital time (mean number of days), duration of gestation, number of corpora lutea and implantation sites, total number of pups delivered (mean), mean number of live pups per litter and pre- and post-implantation loss (%).
- Sperm parameters were evaluated by one-way analysis of variance followed by Dunnett’s multiple comparison test (epididymal and testicular sperm count and numerical sperm motility parameters) or by Kruskal-Wallis non parametric analysis of variance followed by the Mann-Whitney U test (motility parameters expressed as a percentage and sperm morphology). - Reproductive indices:
- The following parameters were calculated:
- pre-coital time = time between the start of mating and successful copulation
- duration of gestation = time between gestation day 0 and day of delivery
- mating index= (number of females mated/number of females placed with males) x 100
- male fertility index = (number of males that became sire/number of males placed with females) x 100
- female fertility index = (number of pregnant females/number of females placed with males) x 100
- female fecundity index =(number of pregnant females/number of females mated) x 100
- gestation index = (number of females with live pups/number of females pregnant) x 100
- pre-implantation loss = [(number of corpora lutea – number of implantation sites)/number of corpora lutea] x 100 - Offspring viability indices:
- The following parameters were calculated:
- live birth index = (number of pups born alive/number of pups born) x 100
- viability index day n-m = (number of pup surviving m days/number of liveborn on day n) x 100
- pup mortality day n = (number of dead pups on day n/total number of pups on day n) x 100
- sex ratio day n = (number of live male pups on day n/ number of live pups on day n) x 100
- number of lost implantations = number of implantations sites - number of pups born alive
- post-implantation loss = [(number of implantation sites - number of pups born alive)/number of implantation sites] x 100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
Details on results (P0)
No treatment-related clinical signs or mortality (the death of one low-dose female and one high-dose female on day 4 of lactation was unrelated to treatment).
BODY WEIGHT (GAIN) AND FOOD CONSUMPTION
Body weight, body weight gain and food consumption (expressed as g/animal/day) of male and female rats of the high-dose group were statistically significantly decreased during the entire or substantial parts of the study. Mean terminal body weights of high-dose rats were 11% (males) or 3% (females) lower compared to controls; at the end of the premating period, high-dose females were about 6% lighter than controls. During gestation, mean body weights of high-dose females remained statistically signficantly lower compared with controls but weight gain was not significantly affected. During lactation, no statistically significant intergroup differences in body weight or weight gain occurred.
TEST SUBSTANCE INTAKE
Substance intake in successive weeks was calculated from the nominal dietary concentrations. As the test material was not stable over a 1-day storage period in the animal room, the actual test material intake was lower than indicated below (compared to the concentration measured at the start of the storage period, the concentration measured after storage was decreased by 18%, 27% and 22% at the low-, mid- and high-dose, respectively).
The mean (range) intakes in mg test material/kg bw/day (not corrected for instability) were:
- Premating males: 16 (11-26) at the low-dose, 58 (41-86) at the mid-dose, 202 (144-287) at the high-dose.
- Premating females: 15 (12-20) at the low-dose, 56 (45-73) at the mid-dose, 171 (139-214) at the high-dose.
- Gestation females: 14 (13-16) at the low-dose, 51 (46-59) at the mid-dose, 165 (161-190) at the high-dose.
- Lactation females: 14 at the low-dose, 45 at the mid-dose, 195 at the high-dose.
HAEMATOLOGY
Red blood cell and coagulation parameters were not affected by treatment.
Total white blood cell count and absolute numbers of lymphocytes, neutrophils, eosinophils, basophils and monocytes were statistically significantly decreased in high-dose males. To a lesser extent, total and differential white blood cell values in males of the low- and mid-dose groups were also decreased compared to concurrent controls. As the mean and individual values in the low- and mid-dose groups were within the historical control range, the lower values in the intermediate dose groups were not ascribed to treatment.
CLINICAL CHEMISTRY
Treatment-related changes in clinical chemistry values were limited to higher chloride concentrations in males at all dose levels (statistically significant at the low- and high-dose) and a lower potassium concentration in high-dose males. These changes might be related to the effect on the kidneys observed in males.
A few other statistically significant differences from controls occurred (lower aspartate aminotransferase in females at all dose levels, lower alkaline phosphatase in mid-dose females and lower albumin in low-dose females) but were not ascribed to treatment (reason: lack of dose dependence).
NEUROBEHAVIOUR
Functional observational screen parameters, fore- and hindlimb grip strength, and spontaneous motor activity (total distance moved and habituation of activity) were not affected by treatment.
ORGAN WEIGHTS
Relative kidney weight was statistically significantly increased in high-dose males. This finding was likely to be related to the alpha 2-microglobulin nephropathy observed in males.
Other statistically significant findings were not ascribed to treatment (slightly lower absolute brain weight in high-dose males, higher absolute and relative adrenal weight in mid-dose females and lower testicular parenchyma weight in the high dose males).
GROSS PATHOLOGY
Macroscopic examination revealed no treatment-related changes.
HISTOPATHOLOGY
A dose-dependent increase of hyalin droplet nephropathy was found in the male animals, characterised by an abundant presence of eosinophilic hyalin droplets in the proximal tubular cells, and several dilated tubuli filled with eosinophilic debris in the corticomedullary area. This change was accompanied by a dose-dependent increase in basophilic tubuli. Compared with concurrent controls, the high-dose males showed increased alpha 2-microglobulin staining of the cortical tubular epithelial cells and of the corticomedullary tubular cell debris. Alpha 2-microglobulin nephropathy in male rats is generally regarded as of no relevance for humans.
REPRODUCTIVE FUNCTION: SPERM MEASURES
Testicular sperm count and epididymal sperm motility, count and morphology were not affected by treatment. The weight of the testicular parenchyma in the high-dose group was statistically significantly lower than in the control group. Since no effects were observed on testis weight, this is considered an incidental finding.
REPRODUCTIVE PERFORMANCE
- Fertility was not affected by treatment (pre-coital time, mating index, duration of gestation, gestation index, male and female fertility indices and female fecundity index were comparable in all groups). The number of pregnant females was 11, 12, 12 and 10 in the control, low-, mid- and high-dose group, respectively.
- The number of corpora lutea was statistically significantly decreased in the high-dose group (mean per animal: 10.1 versus in concurrent controls 12.7 ). Consequently, the numbers of implantation sites and pups delivered were also decreased in this group. The number of corpora lutea in the high-dose group was also lower compared to historical controls (range 11.0-14.5) but higher than lower numbers of corpora lutea observed incidentally in intermediate dose groups of other studies conducted at the testing laboratory (lowest value observed: 8.7). Therefore, the lower number of corpora lutea in the present high-dose group is of doubtful toxicololgical significance and probably due to chance.
- Pre- and post-implantation loss were not affected by treatment.
Effect levels (P0)
open allclose all
- Dose descriptor:
- other: NOAEL (general toxicity)
- Effect level:
- 750 other: mg/kg diet (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on reduced body weight (gain) and food consumption in both sexes and decreases in total and differential white blood cells (all cell types) in males at the next dose level.
- Dose descriptor:
- other: NOAEL (general toxicity)
- Effect level:
- ca. 42 other: mg/kg bw/day based on dietary concentration corrected for measured decrease upon storage in animal room (-27% after 24 hr)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Based on reduced body weight (gain) and food consumption and decreases in total and differential white blood cells (all cell types) at the next dose level.
- Dose descriptor:
- other: NOAEL (general toxicity)
- Effect level:
- ca. 41 other: mg/kg bw/day based on dietary concentration corrected for measured decrease upon storage in animal room (-27% after 24 hr)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Based on reduced body weight (gain) and food consumption at the next dose level.
- Dose descriptor:
- other: NOAEL (reproductive toxicity)
- Effect level:
- ca. 158 other: mg/kg bw, based on dietary concentration corrected for measured decrease upon storage in animal room (-22% after 24 hr)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No male fertility related effects were seen up to the highest dose level tested (2500 mg/kg diet, providing ca. 158 mg/kg bw/day).
- Dose descriptor:
- other: NOAEL (reproductive toxicity)
- Effect level:
- ca. 129 other: mg/kg bw/day based on dietary concentration corrected for measured decrease upon storage in animal room (-22% after 24 hr)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No female fertility related effects were seen up to the highest dose level tested (2500 mg/kg diet, providing ca. 133, 129 and 152 mg/kg bw/day during premating, gestation and lactation, respectively).
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Details on results (F1)
Viability was not affected by treatment. The live birth index and the number (stillborn pups) and percentage (pup mortality day 1) of pups found dead on day 1 were comparable between the groups.
The number of pups lost between days 1-4 in the high-dose group was lower than that in the control and intermediate-dose groups. The higher pup loss in the latter groups was mainly due to the total loss of 2 litters in each of these groups and considered unrelated to treatment.
LITTER SIZE AND SEX
The mean number of pups delivered in the high-dose group was statistically significantly lower than in the control group (8.4 at the high-dose versus 11.2 in controls). This was due to the lower number of corpora lutea (probably due to chance) in the high-dose group.
The sex ratio on days 1 and 4 was not affected by treatment.
CLINICAL SIGNS
No treatment-related findings. In the high-dose group on day 1, the number of cold pups and pups with no milk in the stomach was statistically significantly lower than in the control group. This was due to a relatively high incidence of this finding in controls.
BODY WEIGHT
Pup weight on lactation days 1 and 4 and weight gain between days 1-4 were not affected by treatment.
GROSS PATHOLOGY
Macroscopic examination of stillborn pups and pups that died during the study revealed no treatment-related abnormalities.
Effect levels (F1)
- Key result
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In an oral (diet) Combined Repeated Dose Toxicity Study with Reproduction / Developmental Toxicity Screening Test in rats (OECD 422; 10-week premating period), a NOAEL for parental toxicity of 750 mg/kg diet (ca. 42 and 41 mg/kg body weight/day in males and females, respectively) was established, based on decreases in body weight gain, food consumption and total and differential white blood cell counts. No adverse effects on fertility of the parents or on development of the offspring were noted in any group (NOAEL 2500 mg/kg diet, which provided ca. 158 and 129 mg/kg bw/day in males and females, respectively). The NOAELs expressed as mg/kg bw/day were based on nominal dietary test material concentrations corrected for loss on storage in the animal room.
- Executive summary:
The reproductive / developmental toxicity upon repeated oral exposure was examined in a GLP-compliant study performed according to OECD guideline 422 (TNO Triskelion, 2012). Groups of 12 male and 12 female Wistar rats received the test material via their diet, at concentrations of 0, 200, 750 and 2500 mg/diet during a 10-week premating period and during mating (one week), gestation and lactation until postnatal day 4. The total exposure duration was up to 83 days in male rats and up to 103 days in female rats.
Homogeneity and correct concentration of the test material in the diet were confirmed by analysis. The test substance was not stable in the diet upon storage in the animal room. The decrease in concentration during a 1-day storage period was 18%, 27% and 22% at the low-, mid- and high-dose, respectively. To minimize loss of test material under experimental conditions as much as possible, the feed in the feed hoppers was replaced daily by a fresh portion from the freezer (stability in the freezer was confirmed by analysis). Moreover, the fresh feed was provided in the afternoon instead of in the morning because rats eat most of their feed during the dark period.
The following endpoints were evaluated to assess general toxicity: daily clinical observations, neurobehavioural examination (grip strength; functional observational battery including sensory reactivity to different stimuli; spontaneous motor activity), body weight, food consumption, routine haematology and clinical chemistry (in week 10 of the premating period), organ weights, macroscopic examination and histopathological examination of a wide range of tissues and organs (except for the kidneys which were examined in all groups, only high-dose animals and controls were subjected to histopathology). Endpoints to assess reproductive / developmental toxicity included parental fertility and reproductive performance (sperm analysis, weight and morphology of sex organs, mating index, pre-coital time, male and female fertility indices, female fecundity index, gestation index and length, pre- and post-implantation loss) and litter data (numbers of stillborn, live and dead pups, external abnormalities, pup weight on lactation days 1 and 4, necropsy of stillborn pups and pups that died during the study).
The results showed no treatment-related changes at 200 and 750 mg/kg diet. At 2500 mg/kg diet, body weight (gain) and food consumption were statistically significantly decreased during the entire or substantial parts of the study in rats of both sexes, and total and differential white blood cell counts were decreased in male rats. In addition, male rats showed renal changes consisting of an increased relative kidney weight (at the high-dose level) and a dose-dependent increase of alpha 2-microglobulin nephropathy. This type of nephropathy in male rats is generally regarded as of no relevance for humans. The changes in clinical chemistry values in male rats (higher chloride at all dose levels and lower potassium at the high-dose) might be related to the nephropathy.
Based on these results the NOAEL for general toxicity was 750 mg/kg diet. This dietary level provided ca. 42 mg/kg bw/day in male rats and ca. 41 mg/kg bw/day in female rats (based on the overall mean substance intake during the premating period). The intake of the test material per kg body weight was calculated from the nominal dietary concentration corrected for the loss measured after storage in the animal room for one day.
Testicular sperm count and epididymal sperm motility, count and morphology were not affected by treatment. The weight of the testicular parenchyma in the high-dose group was statistically significantly lower than in the control group. Since no effects were observed on testis weight, this is considered an incidental finding. No female reproductive toxicity parameters were affected except for a slight statistically significant decrease in corpora lutea compared to the historical controls.The observed decrease in corpora lutea is of doubtful toxicological relevance and probably due to chance.Pre- and post-implantation loss were not affected by treatment.
The viability of pups was not affected by treatment The mean number of pups delivered in the high-dose group was statistically significantly lower than in the control group. This was due to the lower number of corpora lutea (probably due to chance) in the high-dose group. No treatment-related clinical findings or body weight changes were observed. Macroscopic examination of stillborn pups and pups that died during the study revealed no treatment-related abnormalities.
The NOAEL for fertility and reproductive performance of the male and female parental rats and the NOAEL for developmental toxicity were 2500 mg/kg diet based on the absence of reproductive effects up to the highest dose tested. This dietary level provided ca. 158 mg/kg bw/day in male parental rats and ca. 129 mg/kg bw/day in female parental rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)